Table 1.
Animal IDs, SIV inoculum, duration of infection, viral loads and colon histopathology in vehicle or delta-9-tetrahydrocannabinol (Δ9-THC) treated chronic SIV-infected and uninfected rhesus macaques.
| Animal ID | SIV inoculum | Duration of infection | Plasma viral loads 106/mL | Colon viral loads 106/mg RNA | Colon histopathology | Opportunistic infections |
|---|---|---|---|---|---|---|
| CHRONIC SIV-INFECTED AND VEHICLE Treated (GROUP 1) FOR MIRNA AND GENE EXPRESSION STUDIES | ||||||
| FT11# | SIVmac251 | 145 | 500 | 2,075 | Mild colitis | ND |
| GH25# | SIVmac239 | 148 | 30 | 3,418 | Mild suppurative colitis | ND |
| HB31# | SIVmac251 | 180 | 3,000 | 200 | Lymphoid hyperplasia | ND |
| GA19# | SIVmac251 | 180 | 100 | 600 | Lymphoid hyperplasia | ND |
| HD08# | SIVmac251 | 90 | 37 | 3,000 | Moderate colitis/cryptitis | ND |
| IH96# | SIVmac251 | 180 | 0.1 | 786 | Lymphoid hyperplasia | ND |
| HV48# | SIVmac251 | 150 | 4 | 147 | ND | ND |
| IN24 | SIVmac251 | 180 | 9.4 | 29 | ND | ND |
| JC81 | SIVmac251 | 180 | 0.38 | 320 | ND | ND |
| CHRONIC SIV-INFECTED AND VEHICLE TREATED (GROUP 1) FOR IMMUNOPHENOTYPING STUDIES | ||||||
| JH47* | SIVmac251 | 180 | 2 | 300 | ND | ND |
| JR36* | SIVmac251 | 180 | 0.5 | 20 | ND | ND |
| JD66* | SIVmac251 | 180 | 0.04 | 4 | ND | ND |
| IV95* | SIVmac251 | 180 | 0.02 | 2 | ND | ND |
| CHRONIC SIV-INFECTED AND Δ9-THC TREATED (GROUP 2) FOR MIRNA AND GENE EXPRESSION STUDIES | ||||||
| GV60# | SIVmac251 | 180 | 18.9 | 6,726 | ND | ND |
| HT48# | SIVmac251 | 150 | 260 | 9,360 | ND | ND |
| IA83# | SIVmac251 | 180 | 1.5 | 1,261 | ND | ND |
| IH69# | SIVmac251 | 180 | 0.06 | 93.8 | ND | ND |
| HI09 | SIVmac251 | 180 | 0.01 | 3.0 | ND | ND |
| JB82 | SIVmac251 | 180 | 7.7 | 970 | ND | ND |
| IA04 | SIVmac251 | 150 | 0.66 | 35 | Mild colitis | ND |
| AL6094# | SIVmac251 | 300 | NA | 40 | ND | ND |
| CHRONIC SIV-INFECTED AND Δ9-THC TREATED (GROUP 2) FOR IMMUNOPHENOTYPING STUDIES | ||||||
| JI45* | SIVmac251 | 180 | 3 | 10 | ND | ND |
| JT80* | SIVmac251 | 180 | 1 | 300 | ND | ND |
| JC85* | SIVmac251 | 180 | 0.02 | 1 | ND | ND |
| IV90* | SIVmac251 | 180 | 0.02 | 10 | ND | ND |
| UNINFECTED CONTROLS (GROUP 3) | ||||||
| EL66 | NA | NA | NA | NA | NA | NA |
| EH70 | NA | NA | NA | NA | NA | NA |
| EH80 | NA | NA | NA | NA | NA | NA |
| HT22 | NA | NA | NA | NA | NA | NA |
| HF54 | NA | NA | NA | NA | NA | NA |
| HR42 | NA | NA | NA | NA | NA | NA |
NA, Not applicable; ND, None detected.
Denotes animals used for immunophenotyping studies, # Denotes animals used for gene (mRNA profiling) expression studies.
All animals including uninfected controls with exception of the eight denoted by an asterisk (*) were used for microRNA profiling.
Note that all five vehicle untreated (FT11-HD08) and only one out of eight vehicle treated (IH96-IV95) macaques showed colon histopathology. However, normalized microarray signal intensity and delta CT values for MNP2, also known as defensin alpha-2 (DEFA2) in Figure S1 showed significant upregulation of MNP2 in vehicle treated (IH96, HV48, IA24, JC81) and untreated (FT11, GH25, HB31, GA19, HD08) macaques suggesting vehicle treatment does not influence inflammatory gene expression in colon despite the absence of detectable histopathological lesions.